Assessment of the Effect of Hypoglossal Nerve Stimulation Therapy on the Site of Collapse During DISE
Overview
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- University Hospital, Antwerp
- Enrollment
- 58
- Locations
- 1
- Primary Endpoint
- Δ%area-of-collapse at the level of the lateral walls
Overview
Brief Summary
The purpose of this study is to assess the site, pattern and degree of upper airway collapse before and during hypoglossal nerve stimulation (HNS) treatment using clinical standard drug-induced sleep endoscopy (DISE) and using a novel, non-invasive method predicting site of collapse from raw polysomnography (PSG) data.
Furthermore, outcomes will be compared between responders and non-responders.
Detailed Description
Patients who will receive hypoglossal nerve stimulation therapy will be recruited at the pre-operative consultation at the department of ENT. As part of the standard procedure, all patients who are eligible for HNS have already undergone DISE.
To be included in the study, the patient should have undergone or is scheduled to undergo a baseline PSG within two years of HNS implantation.
All patients will undergo HNS-implantation and receive HNS-therapy as part of the standard pathway.
One year after HNS-therapy, patients will undergo another PSG as part of routine practice in these patients. An additional DISE will be performed to assess the effect of HNS on the site, pattern and degree of upper airway collapse.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Basic Science
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •18 years or older.
- •Eligible for HNS-therapy:
- •AHI between 15 and 65 events/hour
- •BMI under 32 kg/m2
- •Absence of complete concentric collapse of palate (CCC) on DISE
- •Intolerance or failure of continuous positive airway pressure (CPAP)-treatment
- •Intolerance or failure of mandibular advancement device (MAD)-treatment
- •Combination of central and mixed apneas less than 25% of total apneas on recent PSG (not older than two years)
- •Scheduled for HNS-implantation at the Antwerp University Hospital
- •Capable of giving informed consent
Exclusion Criteria
- •Patients will not receive HNS-therapy at the Antwerp University Hospital
- •Known medical history of intellectual disability, memory disorders or current psychiatric disorders (psychotic illness, major depression, or acute anxiety attacks as mentioned by the patient).
Outcomes
Primary Outcomes
Δ%area-of-collapse at the level of the lateral walls
Time Frame: Between baseline and one year follow-up
The percentage of the area of collapse at the level of the lateral walls - measured using DISE - will be calculated using ImageJ software. The percentage difference of collapse between baseline and one-year follow-up will be calculated.
Secondary Outcomes
- Non-invasive site and pattern of collapse(At baseline and at one-year follow-up)
- Δ%area-of-collapse at the level of the palate, tongue base and epiglottis(Between baseline and one year follow-up)
- Δ%area-of-collapse at each possible site of upper airway collapse (palate, lateral walls, tongue base, epiglottis) in responders and non-responders(Between baseline and one year follow-up)
- DISE-score during baseline DISE and during one-year follow-up DISE.(At baseline and at one-year follow-up)